# IQVIA Holdings Inc.  Share Price Target ‘$266.78’, now 10.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/iqvia-holdings-inc.share-price-target-266.78-now-10.5-upside-potential/4121143455
- Published: 2024-02-20T13:28:10+00:00
- Author: Charlotte Edwards

**IQVIA Holdings Inc.** which can be found using ticker (IQV) now have 18 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The range
between the high target price and low target price is between $300.00 and $235.00
suggesting an average analyst share price target price of $266.78. (at the time 
of writing). Now with the previous closing price of $241.47 this would imply there
is now a potential upside of 10.5%. The day 50 moving average is $220.72 and the
200 moving average now moves to $210.71. The total market capitalization for the
company now stands at 43.31B. The current share price for the company is: $238.60
USD

 The potential market cap would be $47,845,067,946 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of 32.68, revenue per share of $81.52 and a 4.98% return on assets.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions
and clinical research services to the life sciences industry. The Company operates
through three segments: Technology & Analytics Solutions, Research & Development
Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions
segment provides critical information, technology solutions and real-world insights
and services to the Company’s life science clients. The Research & Development Solutions
segment primarily serves biopharmaceutical customers, providing outsourced clinical
research and clinical trial related services. The Contract Sales & Medical Solutions
segment provides health care provider, including contract sales and patient engagement
services to both biopharmaceutical clients and the broader healthcare market. The
Company protects individual patient privacy. The Company conducts business in more
than 100 countries.

Share on:
